Welcome to the Mayo Nephrology Collaborative Group (MNCG) web page. The MNCG is a consortium of nephrologists including Mayo Clinic Rochester, Jacksonville, and Scottsdale, and clinical and academic nephrologists located across the United States interested in developing and conducting prospective studies aimed at treating patients with renal parenchymal diseases. Established in 1988 by Dr. James V. Donadio Jr. and collaborators, the consortium has grown to now encompass 30 clinical centers and involves the participation of many physicians and coordinators who are seeing the vast majority of patients with parenchymal renal diseases early in the course of illness, at a time when promising new therapies may exert their greatest influence.
The members of the MNCG believe strongly that clinical research goes hand in hand with our roles as clinicians and educators, and that this research is crucial for developing new therapies for patients with renal parenchymal diseases. In addition, the work of the MNCG leads to the rapid diffusion of new discoveries because of the number of practices it affects. Both from the intra- and extramural point of view, the role of the clinical research conducted by the MNCG, has contributed to better patient care, and has served an educator to the nephrology community worldwide through its publications. Over the first 15 years, the focus of investigations has been on the clinico-pathologic and therapeutic aspects of IgA nephropathy, now recognized as the most common primary glomerulonephritis in the world.
Breakthroughs in treatment of the disease with omega-3 polyunsaturated fatty acids and mechanisms of actions of these agents on glomerular injury have drawn international recognition to our group. However, for most patients with renal parenchymal diseases, treatment remains unsatisfactory. Recent developments in biotechnology have resulted in the availability of a significant number of new and very promising agents that may be beneficial to renal patients. These medications have yet to be tested in this patient population.